Clinical trials: Liver Tumour
Hepatocellular Carcinoma (HCC)
Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer
This study is for people with unresectable or advanced hepatocellular carcinoma who have not received previous systemic treatment for liver cancer. The study will compare lenvatinib plus tislelizumab with or without gefitinib.
- Trial name
- LENTIG-HCC (NCT07829926)
- Testing
- Lenvatinib, Tislelizumab, Gefitinib
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Carcinoma, Hepatocellular
Adjuvant TACE to Reduce the HCC Recurrence After Resection
Hepatocellular carcinoma (HCC) is the sixth most common malignancies worldwide and the second leading cause of cancer-related death.
- Trial name
- NCT02788526
- Testing
- Adjuvant TACE, Follow-up
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC)
The study is designed to determine whether loading doxorubicin (a type of chemotherapy), when loaded onto a drug eluting microsphere will result in increased destruction of a tumor.
- Trial name
- NCT01116635
- Testing
- doxorubicin, superabsorbent polymer microspheres, embolotherapy
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma, Liver, Cancer of, Primary Resectable
Celiac plExus Block to Reduce OpioID Consumption Following Hepato-pancreato-biliary Mini-invasive Surgery
The goal of this study is to assess the efficacy of intraoperative celiac plexus block (CPB) to reduce opioid consumption following laparoscopic hepato-pancreato-biliary surgery
- Trial name
- CEBOIDS (NCT06214533)
- Testing
- Ropivacaine 0.5%, Normal Saline
- Volunteers
- 60 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Hepatocellular Carcinoma
Pharmacogenetic of Doxorubicin in HCC.
The study included 81 HCC patients, both male and female. Prior to being assessed for eligibility, each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.
- Trial name
- NCT06313047
- Testing
- Doxorubicin
- Where
- Saudi Arabia
- Volunteers
- 81 people
- Sponsor
- Rehab Werida
Colorectal Cancer, Colorectal Neoplasms
Early Detection of Advanced Adenomas and Colorectal Cancer
This study aims to develop a highly sensitive, specific, and cost-effective blood assay for early detection of colorectal adenomas and cancer, using advanced machine learning and state-of-the-art biological analyses.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Colorectal Adenocarcinoma
- Trial name
- AACRC (NCT06342440)
- Testing
- DENEB
- Where
- 6 sites in United States, China and 3 more
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Colorectal Cancer Metastatic, Liver Metastases
Chemotherapy and Tumor Clearance in Hepatic Resections for Colorectal Liver Metastases.
Retrospective analysis of a prospectively collected database of 170 patients between 2004 and 2020, who underwent liver resections for CRLM (colorectal liver metastases) at The Queen Elizabeth Hospital trying to determine rates…
- Trial name
- NCT05273489
- Testing
- Hepatectomy
- Volunteers
- 170 people
- Sponsor
- Hospital Maciel
Liver Cirrhosis
Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis
The investigators will investigate the usefulness of biannual ultrasonography versus annual non-contrast magnetic resonance imaging for surveillance of hepatocellular carcinoma in single arm patients.
- Trial name
- MAGNUS-HCC (NCT02551250)
- Testing
- annual noncontrast MRI, biannual ultrasonography
- Where
- 6 sites in South Korea
- Volunteers
- 211 people
- Sponsor
- JOON-IL CHOI
Neuroendocrine Tumors, Brain (Nervous System) Cancers
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
A research study of liver perfusion (how blood flows to the liver over time). We hope to learn whether perfusion characteristics of liver masses may be predictive of response to treatment and whether liver perfusion…
- Conditions
- Neuroendocrine Tumors, Brain (Nervous System) Cancers, Colon/Rectal Cancer, Colon Cancer
- Trial name
- NCT01163526
- Testing
- CT perfusion
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Stanford University
Malignant Neoplasms
A Study of DEG6498 in Participants With Solid Tumors
The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors.
- Trial name
- NCT07244835
- Testing
- DEG6498
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Degron Therapeutics Co.
Gastric Cancer, Hepatocellular Carcinoma
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
This is a Phase II, open-label, single dose level study of PRL3-ZUMAB monotherapy in patients with advanced solid tumours that have failed standard therapy.
- Conditions
- Gastric Cancer, Hepatocellular Carcinoma, Advanced Solid Tumor
- Trial name
- NCT04118114
- Testing
- PRL3-zumab
- Where
- Singapore
- Volunteers
- 14 people
- Sponsor
- National Cancer Centre, Singapore
Hepatocellular Carcinoma (HCC)
STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma
STRATHEP develops and validates a multimodal AI model to predict treatment response in advanced hepatocellular carcinoma. By integrating digital pathology and MRI radiomics, the project identifies patients likely to benefit from…
- Trial name
- STRATHEP (NCT07863258)
- Where
- 5 sites in Belgium
- Volunteers
- 280 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Hepatic Complications, Malignant Neoplasm
Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. This phase I trial is studying the side effects and best dose of bortezomib in treating patients with advanced cancer and liver…
- Trial name
- NCT00091117
- Testing
- bortezomib, pharmacological study
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Primary Liver Cancer
Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
A phase II clinical trial of stereotactic radiosurgery versus radiofrequency ablation in the treatment of inoperable primary liver cancer in specific sites
- Trial name
- NCT06766643
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Radiofrequency ablation therapy
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00030108
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Perihilar Cholangiocarcinoma
Extent of Intrahepatic Infiltration of Perihilar Cholangiocarcinoma
The extent of intrahepatic infiltration of perihilar cholangiocarcinoma (PHCC) remains unclear. This research aimed to explore the pattern and extent of intrahepatic infiltration of PHCC to guide surgical treatment and…
- Trial name
- NCT06357117
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Hepatocellular Carcinoma
TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)
For patients with advanced HCC not suitable for resection or liver transplantation but without extrahepatic manifestations, local therapy with TACE is regarded as standard treatment.
- Trial name
- SOCRATES (NCT00618384)
- Testing
- Sorafenib
- Where
- 6 sites in Germany
- Volunteers
- 43 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Liver Failure, Kidney Failure
Mesenchymal Stem Cells After Renal or Liver Transplantation
The immune system of a patient can attack the liver or the kidney received from a donor (organ rejection). This can be prevented by treating these patients long-life with immunosuppressive drugs.
- Trial name
- NCT01429038
- Testing
- Mesenchymal Stem Cells
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- University of Liege
Hepatocellular Carcinoma
Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with radiofrequency ablation (RFA) and transcatheter arterial chemoembolization(TACE) in patients with…
- Trial name
- NCT04157140
- Testing
- Anlotinib, TACE+RFA
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Jinglong Chen
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.